On the other side, the high frequency of TP53 disruption in both clonally related and clonally unrelated DLBCL-type RS mandates the analysis of this genetic lesion in the RS sample, since TP53 disruption is a consolidated predictor of chemorefractoriness in the context of both CLL and DLBCL arising de novo [73,74]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.